Bharat Biotech Releases Covaxin's Phase 3 Trial Data, Claims 77.8% Efficacy

Bharat Biotech has released the final phase 3 efficacy data. The company claims it's made in India vaccine, Covaxin, has shown overall efficacy of 77.8%. The data, however, is yet to be peer-reviewed.

Related Videos